Pridopidine PREVAiLS Phase 3 — Sigma-1 Receptor Agonist for ALS
Pridopidine is an oral sigma-1 receptor (S1R) agonist developed by Prilenia Therapeutics and Ferrer for ALS. After a mixed result in the HEALEY ALS Platform Trial — the primary endpoint was missed in the full population, but a subgroup of patients with early, rapidly progressive ALS showed 32% slower functional decline — the FDA cleared a dedicated Phase 3 trial targeting exactly that subgroup. PREVAiLS (PRidopidine's Effect on VentilAtion In ALS patients study) enrolled its first participant in April 2026. With up to 500 patients across 60 centers in 13 countries, it is reportedly the only currently recruiting pivotal Phase 3 ALS trial.
Mechanism of action: sigma-1 receptor activation
The sigma-1 receptor (S1R) is an intracellular chaperone protein located at the interface between the endoplasmic reticulum and mitochondria. It plays roles in cellular calcium homeostasis, mitochondrial function, ER stress responses, and the processing of misfolded proteins — all of which are mechanisms implicated in motor neuron vulnerability and death in ALS.
Pridopidine acts as a selective agonist at the sigma-1 receptor. In preclinical ALS models, S1R activation has been shown to protect motor neurons against ER stress, reduce protein aggregation, and improve mitochondrial function. The drug is orally bioavailable and penetrates the blood-brain barrier, reaching concentrations in the CNS consistent with therapeutic S1R occupancy.
Pridopidine's mechanism is not mutation-specific — it does not target SOD1, C9orf72, FUS, or any other specific genetic cause of ALS. It targets a general cellular stress response pathway implicated broadly in motor neuron disease. This makes it potentially relevant to sporadic ALS and, theoretically, to other motor neuron conditions.
Prior evidence: from HEALEY to PREVAiLS
Pridopidine was evaluated as one regimen in the HEALEY ALS Platform Trial at Massachusetts General Hospital. In the full enrolled population of that arm — 120 participants on pridopidine, 164 on shared placebo — the primary endpoint of slowing overall ALSFRS-R decline was not met.
However, a pre-specified subgroup analysis of 284 participants with early, rapidly progressive ALS (defined as ALS onset within 18 months of symptom onset) showed a different picture. In this subgroup, pridopidine produced 32% slowing of ALSFRS-R decline at 24 weeks (P = 0.03). Secondary outcomes were even more striking: 62% reduction in respiratory function worsening and 88% slowing of dyspnea decline at 24 weeks. A separate survival analysis suggested a 57% improvement in median survival, with median time extended from approximately 300 to 600 days.
These subgroup results have the limitations of any subgroup analysis — they were not the primary endpoint, and subgroup findings can reflect chance especially when multiple subgroups are examined. The FDA reviewed this data and cleared the Phase 3 PREVAiLS trial specifically designed to enroll the subgroup population — patients with early, rapidly progressive ALS — and to use the ALSFRS-R slope over 48 weeks as the primary endpoint.
PREVAiLS trial design
PREVAiLS is a 48-week double-blind, placebo-controlled Phase 3 trial targeting patients with early, rapidly progressive ALS — specifically those with ALS onset within 18 months of symptom onset. Enrollment target is up to 500 patients across up to 60 centers in 13 countries. The trial design includes a 48-week double-blind treatment phase followed by an open-label extension.
The first participant was enrolled in April 2026. Enrollment is expected to be ongoing through 2026 and into 2027 depending on recruitment pace. Pridenia Therapeutics and Ferrer have described PREVAiLS as the only pivotal Phase 3 ALS trial currently recruiting — a claim that reflects the current state of the ALS pipeline rather than a permanent status.
Pridopidine showed a safety profile similar to placebo in the HEALEY trial — one of the conditions for advancing to Phase 3. The drug is well tolerated at the doses being studied.
Why it matters
If PREVAiLS succeeds, pridopidine would become the first new ALS approval targeting a non-genetic mechanism since edaravone in 2017 (and before AMX0035's subsequent market withdrawal). A sigma-1 receptor agonist would represent a genuinely different approach from riluzole's glutamate antagonism and edaravone's antioxidant mechanism.
The 32% HEALEY subgroup result is meaningful but needs Phase 3 confirmation before conclusions can be drawn. The ALS drug development history — where multiple Phase 2 signals have not survived Phase 3 replication — makes appropriate caution essential. At the same time, the specificity of the target population (early, rapidly progressive ALS) and the FDA's endorsement of the trial design provide more confidence than typical Phase 2 extrapolations.
PLS relevance
PREVAiLS enrolls ALS patients, not PLS patients. PLS patients are not eligible for enrollment. The sigma-1 receptor pathway is present in upper motor neurons, which are the cells affected in PLS, making the mechanism potentially relevant — but there is no published data on pridopidine in PLS, and direct applicability cannot be established without a dedicated study.
If PREVAiLS demonstrates efficacy in ALS, the logical next question for the field would be whether S1R activation benefits upper motor neurons in PLS. That study does not currently exist and would require advocacy and funding to initiate.
How this connects
The HEALEY subgroup data that justified PREVAiLS is described in the HEALEY Platform Trial page. For context on the overall ALS drug pipeline, see Drug Trial Research. For the only currently approved targeted ALS therapy — which went through an analogous biomarker-guided development path — see the Tofersen VALOR Trial page. Information on participating in trials is at Clinical Trials.
Citation
Prilenia Therapeutics / Ferrer. PREVAiLS Phase 3 trial of pridopidine for early rapidly progressive ALS. First participant enrolled April 2026. NeurologyLive clinical trial clearance report (2025); ALS News Today April 2026. NCT details pending full registration.